Overcoming Barriers Associated With CDK4/6 Inhibitors

Financial burden, logistical challenges, and patient hesitancy are identified as key obstacles to therapy success. Panelists outline ways to navigate insurance authorizations, patient assistance programs, and pharmacy coordination to prevent treatment delays. They emphasize that proactive communication among clinicians, payers, and patients reduces gaps in access.

Another major barrier involves managing adverse effects that discourage adherence. By providing anticipatory guidance and reinforcing that most toxicities are reversible with dose modification, clinicians help patients remain confident and engaged in therapy. Education and emotional support are crucial in sustaining motivation.

Overcoming barriers requires systemic effort—aligning multidisciplinary teams, streamlining communication, and building infrastructure to support equitable, long-term care for all patients.